Standard BioTools Inc. Operating Lease Liability
Standard BioTools Inc. (LAB) had Operating Lease Liability of $30.53 million as of 2025-12-31, per its 10-K filed 2026-03-16.
Financial Statements › Balance Sheet › Liabilities
us-gaap:OperatingLeaseLiability · last filed 2026-03-16
- 2025-12-31: Operating Lease, Liability $30.53M.
- 2024-12-31: Operating Lease, Liability $32.70M.
- 2024-09-30: Operating Lease, Liability $34.26M.
- 2024-06-30: Operating Lease, Liability $35.47M.
| Period end | Operating Lease, Liability |
|---|---|
| 2025-12-31 | $30.53M 10-K · filed 2026-03-16 |
| 2024-12-31 | $32.70M 10-K · filed 2025-03-11 |
| 2024-09-30 | $34.26M 10-Q · filed 2024-11-06 |
| 2024-06-30 | $35.47M 10-Q · filed 2024-08-06 |
| 2024-03-31 | $36.94M 10-Q · filed 2024-05-09 |
| 2023-12-31 | $34.70M 10-K · filed 2024-03-01 |
| 2023-03-31 | $36.91M 10-Q · filed 2023-05-09 |
| 2022-12-31 | $37.76M 10-Q · filed 2023-05-09 |
| 2022-09-30 | $38.38M 10-Q · filed 2022-11-09 |
| 2022-06-30 | $39.02M 10-Q · filed 2022-08-09 |
| 2022-03-31 | $39.97M 10-Q · filed 2022-05-09 |
| 2021-12-31 | $40.60M 10-K · filed 2023-03-14 |
| 2021-09-30 | $41.04M 10-Q · filed 2021-11-09 |
| 2021-06-30 | $42.03M 10-Q · filed 2021-08-06 |
| 2021-03-31 | $40.44M 10-Q · filed 2021-05-07 |
| 2020-12-31 | $41.15M 10-K · filed 2022-03-08 |
| 2020-09-30 | $41.30M 10-Q · filed 2020-11-09 |
| 2020-06-30 | $41.31M 10-Q · filed 2020-08-07 |
| 2020-03-31 | $40.80M 10-Q · filed 2020-05-11 |
| 2019-12-31 | $6.16M 10-K · filed 2021-02-25 |
| 2019-09-30 | $6.82M 10-Q · filed 2019-11-08 |
| 2019-06-30 | $8.16M 10-Q · filed 2019-08-07 |
| 2019-03-31 | $8.91M 10-Q · filed 2019-05-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |